Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is
A cohort study on the association between acid-suppressing drugs in pregnancy and asthma in the offspring
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| All women exposed to PPI at any time during pregnancy | Exposure to PPI defined as presence of at least one prescription of a PPI any time between last menstrual period and delievry date |
| |
| All women exposed to H2RA at any time during pregnancy | Exposure to H2RA defined as presence of at least one prescription of H2RA any time between last menstrual period and delivery date |
| |
| Pregnant women with no recorded use of acid suppressing drugs | Pregnant women with no recorded use of acid suppressing drugs at any time during pregnancy |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Risk of asthma in offspring | Drug | Exposure to PPI or H2RA, respectively during pregnancy No exposure to acid suppressing drugs during pregnancy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Relative risk of first asthma diagnosis associated with prenatal exposure to proton pump inhibitors | From 1 January 2005 till 31 December 2010, an expected average of 5 years. | |
| Relative risk of first asthma diagnosis associated with prenatal exposure to histamine-2 receptor antagonists | From 1 January 2005 till 31 December 2010, an expected average of 5 years |
Not provided
Not provided
Inclusion Criteria:
- Females aged 18-45 years with at least one pregnancy between 1 January 1995 - 31 December 2010 (see study population description)
Exclusion Criteria:
- Males, females below age 18 and 45 years and above (see study population description)
Not provided
Not provided
Not provided
Not provided
All women aged 18-45 years and with at least one pregnancy between 1 January 1995 and 31 December 2010 who have been enrolled with their PCP (Primary Care Physician) for at least 1 year and have had a health contact in the year prior to the last menstrual period (LMP) of the respective pregnancy. The final study population will include pregnancies that can be unequivocally linked with live birth(s) and only the first pregnancy ascertained during the study period for each woman will be retained
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Luis A Garcia Rodriguez, MD | CEIFE (Centro Espanol de Investigacion Farmacoepidemiologica - Spanish Centre for Pharmacoepidemiologic Research ) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Madrid | Spain |
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |